Do Wall Street Analysts Like Charles River Laboratories Stock?

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services in the United States and internationally. With a market cap of $6.7 billion, the company operates through Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments.

CRL has significantly underperformed the broader market over the past year and in 2025. CRL stock prices have declined 37.2% over the past 52 weeks and 25.9% on a YTD basis, compared to the S&P 500 Index’s ($SPX) 10.2% gains over the past year and a 1.3% decline in 2025.